Cryopreserved platelet (CPP) development for US FDA licensure
Active Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0030
- Awardee
-
Cellphire, Inc. UEI F42VPQJ8LJL4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $70,336,011
Award facts
- Opportunity
-
- Cryopreserved Platelet (CPP) Development for U. S. Food and Drug Administration Licensure Pre-Solicitation · W81XWH19R0033 · Posted May 2, 2019
- Contract value 96% obligated
-
- $70,336,011.48 Current, with exercised options
- $73,623,203.48 Potential, with all options
- Completion date 77% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $10,364,155 | |
| Funding Only Action | $6,752,524 | |
| Funding Only Action | -$6,752,524 | |
| Supplemental Agreement for work within scope | $6,752,524 | |
| Funding Only Action | $9,064,043 | |
| Funding Only Action | -$2,116 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $22,056,023 | |
| Funding Only Action | $1,116,534 | |
| Supplemental Agreement for work within scope | $4,825,248 | |
| Supplemental Agreement for work within scope | $207,641 | |
| Funding Only Action | $656,595 | |
| Supplemental Agreement for work within scope | $2,899,341 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $3,791,481 | |
| Funding Only Action | $1,121,225 | |
| Funding Only Action | $2,800,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $2,096,159 | |
| Original award | $2,587,158 |
Show all 21
About this award
The Defense Health Agency awarded a $73.6 million definitive contract to Cellphire, Inc. for cryopreserved platelet (CPP) development and Phase III clinical trials on December 20, 2019, under a total small business set-away.
The contract pursues FDA licensure of a cryopreserved platelet product through Phase III clinical trials. Place of performance is Rockville, MD. The contract runs through October 31, 2028, on a cost-plus-fixed-fee basis. Cellphire specializes in platelet-derived therapeutics using proprietary stabilization methods for blood products, with prior federal experience in lyophilized canine plasma and cryopreserved human platelet development for military trauma applications.
Quick answers
Who was awarded contract W81XWH20C0030?
W81XWH20C0030 was awarded to Cellphire, Inc. by Defense Health Agency (Department of Defense) on December 20, 2019.
How much is contract W81XWH20C0030 worth?
The government has obligated $70,336,011 on W81XWH20C0030. Its potential value, with all options, is $73,623,203.
Was contract W81XWH20C0030 competed?
The extent of competition for W81XWH20C0030 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award